Wall Street analysts expect Cytosorbents Co. (NASDAQ:CTSO – Get Rating) to announce ($0.15) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Five analysts have issued estimates for Cytosorbents’ earnings, with the lowest EPS estimate coming in at ($0.23) and the highest estimate coming in at ($0.07). Cytosorbents posted earnings per share of ($0.10) during the same quarter last year, which indicates a negative year over year growth rate of 50%. The firm is expected to issue its next earnings results after the market closes on Monday, January 1st.
On average, analysts expect that Cytosorbents will report full year earnings of ($0.64) per share for the current year, with EPS estimates ranging from ($0.89) to ($0.36). For the next financial year, analysts anticipate that the company will post earnings of ($0.35) per share, with EPS estimates ranging from ($0.61) to ($0.12). Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that cover Cytosorbents.
Cytosorbents (NASDAQ:CTSO – Get Rating) last released its quarterly earnings data on Tuesday, March 8th. The medical research company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.08). The business had revenue of $10.78 million during the quarter, compared to analysts’ expectations of $9.72 million. Cytosorbents had a negative net margin of 56.90% and a negative return on equity of 34.49%.
CTSO stock opened at $2.10 on Friday. The firm’s fifty day simple moving average is $3.13 and its 200-day simple moving average is $4.13. Cytosorbents has a 12 month low of $1.89 and a 12 month high of $9.80.
Several institutional investors and hedge funds have recently bought and sold shares of CTSO. SG Americas Securities LLC acquired a new position in Cytosorbents during the third quarter worth $114,000. Sargent Investment Group LLC raised its position in Cytosorbents by 12.6% during the third quarter. Sargent Investment Group LLC now owns 964,141 shares of the medical research company’s stock worth $7,829,000 after acquiring an additional 107,826 shares during the period. Granahan Investment Management Inc. MA raised its position in Cytosorbents by 15.0% during the third quarter. Granahan Investment Management Inc. MA now owns 1,154,561 shares of the medical research company’s stock worth $9,375,000 after acquiring an additional 151,015 shares during the period. Skylands Capital LLC raised its position in Cytosorbents by 5.9% during the fourth quarter. Skylands Capital LLC now owns 1,946,374 shares of the medical research company’s stock worth $8,155,000 after acquiring an additional 108,833 shares during the period. Finally, Avenir Corp raised its position in Cytosorbents by 2.1% during the third quarter. Avenir Corp now owns 1,395,385 shares of the medical research company’s stock worth $11,331,000 after acquiring an additional 28,836 shares during the period. Hedge funds and other institutional investors own 40.98% of the company’s stock.
Cytosorbents Company Profile (Get Rating)
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant.
- Get a free copy of the StockNews.com research report on Cytosorbents (CTSO)
- Why is Chevron Stock Falling After Strong Earnings?
- MarketBeat: Week in Review 4/25 – 4/29
- Apple’s Numbers Complete Trifecta
- Rogers Communication Stock Should Be Launching Higher
- Iridium Communications Stock is Ready to Return to Orbit
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.